(Q40780592)

23 September 2017

title

Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort (English)

1 reference

23 September 2017

1 reference

1 reference

1 reference

4

Armin von Gunten

0 references

Frederik Vandenberghe

Frederik Vandenberghe

1

0 references

Eva Choong

Eva Choong

3

0 references

Monia Guidi

Monia Guidi

2

0 references

Chantal Csajka

Chantal Csajka

6

0 references

Chin B. Eap

Chin B Eap

7

0 references

author name string

Armin von Gunten

4

1 reference

23 September 2017

Philippe Conus

5

1 reference

23 September 2017

language of work or name

1 reference

1 July 2015

1 reference

Clinical Pharmacokinetics

23 September 2017

published in

1 reference

23 September 2017

volume

54

1 reference

23 September 2017

issue

12

1 reference

23 September 2017

page(s)

1259-1272

1 reference

Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Influence of age and gender on risperidone plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Risperidone plasma levels, clinical response and side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

MDR- and CYP3A4-mediated drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Ways to fit a PK model with some data below the quantification limit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Paliperidone extended-release: does it have a place in antipsychotic therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Prolactin and dopamine: what is the connection? A review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0289-8

The pharmacokinetics of risperidone in humans: a summary

21 January 2018

1 reference

12 December 2020

Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.

1 reference

12 December 2020

Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers

1 reference

12 December 2020

Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects

1 reference

12 December 2020

Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite

1 reference

12 December 2020

Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study

1 reference

12 December 2020

Serum Concentrations and Side Effects in Psychiatric Patients During Risperidone Therapy

1 reference

12 December 2020

Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass

1 reference

12 December 2020

Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder

1 reference

12 December 2020

Absorption, metabolism, and excretion of risperidone in humans.

1 reference

12 December 2020

Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate

1 reference

12 December 2020

Human Pregnane X Receptor Genotype of the Donor but Not of the Recipient Is a Risk Factor for Delayed Graft Function After Renal Transplantation

1 reference

12 December 2020

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

1 reference

12 December 2020

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

1 reference

12 December 2020

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

12 December 2020

Management of psychotropic-induced hyperprolactinemia

1 reference

12 December 2020

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

1 reference

12 December 2020

10.1007/S40262-015-0289-8

Identifiers

DOI

1 reference

Dimensions Publication ID

23 September 2017

1039665904

0 references

1 reference